BioSpace News Archive

Business

Autolus Therapeutics announces retirement of chief financial officer and succession plan

Autolus Therapeutics plc announced that Andrew J. Oakley plans to retire from his position as chief financial officer with effect from 31 March 2022 and will concentrate on non-executive director roles.

January 10, 2022
·
5 min read
Genetown

Medically Home Announces a $110 Million Strategic Investment Led by Baxter International Inc., Global Medical Response and Cardinal Health to Advance Leadership in Hospital-Level Patient Care at Home

Medically Home announced a new, $110 million round of funding from strategic investors including Baxter International Inc., Global Medical Response and Cardinal Health who will each have representation on the company’s Board.

January 10, 2022
·
8 min read
Drug Development

Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders

Khondrion announced that the last patient has been dosed with sonlicromanol in the KHENERGYZE Phase IIb clinical study.

January 10, 2022
·
5 min read
Business

Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies.

January 10, 2022
·
5 min read
Business

Sectra appoints new CFO

Jessica Holmquist has been appointed CFO of international medical imaging IT and cybersecurity company Sectra.

January 10, 2022
·
1 min read
EsoCap and Upadia sign exclusive licensing agreement combining EsoCap technology with Upadia antibodies for the treatment of Barrett’s esophagus

EsoCap announced that the company has entered into a worldwide, exclusive antibody licensing agreement with Upadia, to develop targeted therapeutics to treat Barrett’s esophagus.

January 10, 2022
·
5 min read
Business

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results

Sight Sciences, Inc., an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, announced preliminary unaudited financial results for the fourth quarter and year ended December 31, 2021.

January 10, 2022
·
8 min read
Drug Development

Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T

Humanigen, Inc. outlined the next steps for the development of its lead candidate, lenzilumab, in the prevention of CAR-T therapy related toxicities including ICANS and CRS in patients with relapsed or refractory Non-Hodgkin lymphoma.

January 10, 2022
·
6 min read
Genetown

TCR² Therapeutics Announces 2022 Strategic Priorities and Anticipated Milestones

TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, announced its strategic priorities and anticipated milestones for 2022.

January 10, 2022
·
7 min read
BioMidwest

Harrow Health to Participate in H.C. Wainwright BioConnect Conference

Harrow Health, Inc., an ophthalmic-focused healthcare company, announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C. Wainwright BioConnect Conference to be held virtually on January 10-13, 2022.

January 10, 2022
·
1 min read